Skip to content

Released May 12, 2022, after the close

10-Q filed May 12, 2022, 42 days after period end · 0001390478-22-000012

Q1 2022 · 10-Q
Revenue$1.00M−82.5% vs Q1 2021no prior Q4 2021 on file
Net Income-$16.74MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$1.05N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$16,735,000N/M
Operating Cash Flow-$7,150,000N/M
Margins · derived
Operating margin-1673.5%−1634.1 pt vs Q1 2021
Net margin-1674.4%−1632.2 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Revenue$1.00M$5.70M$0.00—
Net Income-$16.74M-$2.40M-$4.14M-$4.54M
EPS Diluted-$1.05-$0.16-$0.66-$11.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR